Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 1 Safety and PK Study of IV TP-271

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03234738
Recruitment Status : Unknown
Verified October 2018 by Tetraphase Pharmaceuticals, Inc..
Recruitment status was:  Active, not recruiting
First Posted : July 31, 2017
Last Update Posted : October 19, 2018
Sponsor:
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
Tetraphase Pharmaceuticals, Inc.

Brief Summary:
This is a single-center, randomized, placebo-controlled, double-blind, multiple-ascending-dose, inpatient study to assess the safety, tolerability, and pharmacokinetics of TP-271 in healthy subjects. Subjects aged 18 to 50 years who fulfill the inclusion/exclusion criteria will be enrolled in this study.

Condition or disease Intervention/treatment Phase
Bacterial Infections Drug: TP-271 Drug: Placebo Phase 1

Detailed Description:

Up to 5 cohorts of 8 subjects each (up to a total of 40 subjects) will be enrolled. The 8 subjects within each cohort will be randomized 6:2 to receive multiple IV doses of TP-271 or placebo. Study drug will be administered IV once daily on the morning of Days 1 through 7 following an overnight fast (minimum 8 hours). The planned doses for study drug for Cohorts A - E are 0.5 mg/kg TP-271 or placebo, 1.0 mg/kg TP-271 or placebo, 2.0 mg/kg TP-271 or placebo, 2.5 mg/kg TP-271 or placebo and 3.0 mg/kg TP-271 or placebo respectively.

During the Screening period (Days -28 to -2 prior to the subject receiving TP-271 or placebo), each subject will be assessed for eligibility. Each subject must sign and date the ICF prior to undergoing any study-related procedures.

All cohorts will follow the same study design. On Day -1, subjects will be admitted to the study unit and eligibility confirmed. On Day 1, eligible subjects will be enrolled and randomized to receive either TP-271 or placebo and will receive the assigned drug from Days 1 through 7. Subjects will be required to stay at the study unit from Days -1 through 11 to assess safety and obtain the required PK samples. On Day 11, subjects will be discharged from the study unit. A final safety assessment will be performed once between Days 14 and 20, 7 to 13 days following administration of the subject's final dose of study drug.

After all 8 subjects in a cohort have completed study procedures through Day 11, the Principal Investigator and the Sponsor's Medical Monitor will evaluate all blinded safety and plasma PK data to determine whether any criteria that would require a meeting of the Safety Monitoring Committee (SMC) are met. If no such criteria are met, the study may proceed to the subsequent cohort at the next higher dose of TP-271 without consulting the SMC.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Five Multiple-Ascending Doses
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: IV bags and lines are covered to prevent unblinding.
Primary Purpose: Other
Official Title: A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenous TP-271 in Healthy Adult Subjects
Actual Study Start Date : August 16, 2017
Estimated Primary Completion Date : October 31, 2018
Estimated Study Completion Date : February 28, 2019

Arm Intervention/treatment
Active Comparator: Cohort A
Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 0.5 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
Drug: TP-271
multiple oral doses of TP-271 or placebo, dosed once daily for 7 days, randomized 3:1, doses escalating as 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 2.5 mg/kg, and 3.0 mg/kg

Drug: Placebo
Placebo is sterile 0.45% saline randomized 3:1 to receive

Active Comparator: Cohort B
Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 1.0 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
Drug: TP-271
multiple oral doses of TP-271 or placebo, dosed once daily for 7 days, randomized 3:1, doses escalating as 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 2.5 mg/kg, and 3.0 mg/kg

Drug: Placebo
Placebo is sterile 0.45% saline randomized 3:1 to receive

Active Comparator: Cohort C
Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 2.0 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
Drug: TP-271
multiple oral doses of TP-271 or placebo, dosed once daily for 7 days, randomized 3:1, doses escalating as 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 2.5 mg/kg, and 3.0 mg/kg

Drug: Placebo
Placebo is sterile 0.45% saline randomized 3:1 to receive

Active Comparator: Cohort D
Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 2.5 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
Drug: TP-271
multiple oral doses of TP-271 or placebo, dosed once daily for 7 days, randomized 3:1, doses escalating as 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 2.5 mg/kg, and 3.0 mg/kg

Drug: Placebo
Placebo is sterile 0.45% saline randomized 3:1 to receive

Active Comparator: Cohort E
Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 3.0 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
Drug: TP-271
multiple oral doses of TP-271 or placebo, dosed once daily for 7 days, randomized 3:1, doses escalating as 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 2.5 mg/kg, and 3.0 mg/kg

Drug: Placebo
Placebo is sterile 0.45% saline randomized 3:1 to receive




Primary Outcome Measures :
  1. Adverse Events [ Time Frame: Throughout the study, ~ 49 days ]
    Incidence, intensity, and type of adverse events (AEs) from the time of signing the informed consent form (ICF) through the EOS Visit

  2. Physical Exams [ Time Frame: ~ 20 days ]
    Changes in physical examination findings between Day -1 and the EOS Visit

  3. Vital Signs [ Time Frame: ~ 20 days ]
    Changes in vital signs from Day -1 through the EOS Visit

  4. Safety Laboratory Results [ Time Frame: ~ 20 days ]
    Changes in safety laboratory (clinical chemistry, electrolytes, hematology, blood glucose, and coagulation) results from Day -1 through the EOS Visit

  5. ECG measurements [ Time Frame: ~ 20 days ]
    Changes in electrocardiogram (ECG) measurements from Day -1 through the EOS Visit


Secondary Outcome Measures :
  1. Assess the Pharmacokinetics (PK) of TP-271in Plasma [ Time Frame: ~11 days ]
    Plasma concentrations of TP-271 and its C-4 epimer, TP-9555, for PK analysis from Days 1 through 11

  2. Assess the Pharmacokinetics (PK) of TP-271 in Urine [ Time Frame: ~11 days ]
    Urine concentrations of TP-271 and its C-4 epimer, TP-9555, from Days 1 through 11



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Be within the age range of 18 to 50 years, inclusive, at the time of Screening
  2. Voluntarily sign an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved ICF to participate in the study after all relevant aspects of the study have been explained and discussed with the subject and before undergoing any study-related procedures
  3. Have a body mass index (BMI) ≥18.0 and ≤33.0 kg/m2
  4. Have a negative history of and negative screening results for human immunodeficiency virus 1 and 2 and hepatitis B and C antibodies
  5. Have the ability to communicate with the study unit staff in a manner sufficient to carry out all protocol procedures as described
  6. For female subjects, be of non-childbearing potential, either 1 year postmenopausal or surgically sterile (bilateral oophorectomy, bilateral tubal ligation, or complete hysterectomy)
  7. For male subjects, be willing and able to use a barrier method of contraception or practice abstinence (including males who had a vasectomy) from dosing through 90 days after administration of the final dose of study drug

Exclusion Criteria:

  1. History and/or presence of any clinically significant disease or disorder such as cardiovascular, pulmonary, renal, hepatic, neurological, gastrointestinal, endocrine, psychiatric, or mental disease or disorder, or mental or legal incapacitation, which, in the opinion of the PI or Sub-Investigator(s), may either put the subject at risk because of participation in the study, influence the results of the study, or influence the subject's ability to participate in the study
  2. Clinical laboratory values that fall outside the eligibility range specified in Appendix D; for laboratory values that are not included in Appendix D, values outside the reference range are exclusionary, with the following exceptions (Table 4. Acceptable Out-of-Range Clinical Laboratory Values
  3. Known allergy to tetracycline antibiotics or to any of the excipients in TP-271
  4. Clinically significant abnormality on a 12-lead ECG, including the following:

    • Rhythm other than sinus
    • Corrected QT interval using Fridericia's formula (QTcF) >450 msec
    • Evidence of second- or third-degree atrioventricular block
    • Pathological Q-waves (defined as Q-wave >40 msec or depth >0.4 to 0.5 mV)
    • Evidence of ventricular pre-excitation
    • Evidence of complete left bundle branch block (BBB), right BBB, or incomplete left BBB
    • Intraventricular conduction delay with QRS duration >120 msec
    • ST segment abnormalities, unless judged by the PI or Sub-Investigator(s) to be non pathologic
  5. History of seizures
  6. History within 3 years of a positive result on a urine screen for drugs of abuse or a positive result at Screening for any of the following drugs of abuse: tetrahydrocannabinols, cocaine, opioids, phencyclidines, amphetamine, benzodiazepine, and barbiturates
  7. Use of tobacco, nicotine, or nicotine-replacement products within 3 months prior to administration of the study drug through the last visit
  8. Typical weekly alcohol consumption of 7 or more alcoholic drinks, where 1 alcoholic drink is defined as 1 glass of beer (approximately 10 to 12 oz), 1 can (12 oz) of beer, 1 glass of wine (approximately 4 to 5 oz), or distilled spirits (approximately 1 oz or 30 mL of liquor)
  9. Alcohol consumption within 48 hours prior to dosing
  10. Participation in a clinical study within 10 half-lives of the prior study drug administration or within the previous 3 months if the half-life or dose of the investigational agent is unknown or planned participation in another clinical study concurrent with the current clinical study
  11. History of difficulty donating blood or poor venous access
  12. Blood donation (1 unit or approximately 350 mL) within 1 month prior to receiving study drug or plans to donate prior to receiving study drug or during the clinical study
  13. Use of any prescription or nonprescription medication, including vitamins or herbal medications, vaccination, or immunization within 7 days or 5 half-lives (if known), whichever is longer, prior to dosing of study drug, with the following exceptions: medications used to treat an AE, and the use of acetaminophen, naproxen, and ibuprofen (except for within 24 hours prior to dosing)
  14. Male subject donates or plans to donate sperm during the study and for at least 90 days after study drug administration.
  15. Unwillingness or inability to follow the procedures outlined in the clinical study protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03234738


Locations
Layout table for location information
United States, Texas
PPD Phase 1 Clinic
Austin, Texas, United States, 78744
Sponsors and Collaborators
Tetraphase Pharmaceuticals, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
Layout table for investigator information
Study Director: Patrick T Horn, MD, PhD Tetraphase Pharmaceuticals
Layout table for additonal information
Responsible Party: Tetraphase Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT03234738    
Other Study ID Numbers: TP-271-002
HHSN272201100028C ( Other Grant/Funding Number: NIAID )
First Posted: July 31, 2017    Key Record Dates
Last Update Posted: October 19, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Bacterial Infections